×
HilleVax Net Current Debt 2022-2025 | HLVX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
HilleVax net current debt from 2022 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
HilleVax Net Current Debt 2022-2025 | HLVX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
HilleVax net current debt from 2022 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$247.1B
Amgen (AMGN)
$155.3B
Gilead Sciences (GILD)
$141.6B
Vertex Pharmaceuticals (VRTX)
$99.7B
Bristol Myers Squibb (BMY)
$96B
GSK (GSK)
$80.7B
CSL (CSLLY)
$67.1B
Regeneron Pharmaceuticals (REGN)
$60.7B
Alnylam Pharmaceuticals (ALNY)
$58.2B
Argenex SE (ARGX)
$41.5B
Insmed (INSM)
$27.1B
BioNTech SE (BNTX)
$25.3B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20B
Incyte (INCY)
$16.6B
Genmab (GNMSF)
$16.2B
Genmab (GMAB)
$15.6B
Illumina (ILMN)
$15.3B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.9B
Exelixis (EXEL)
$10.2B
Moderna (MRNA)
$9.9B
Verona Pharma American Depositary Share (VRNA)
$9.1B
Bio-Techne Corp (TECH)
$8.9B
Exact Sciences (EXAS)
$8.6B
Halozyme Therapeutics (HALO)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.9B